Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Should You Buy?

Posted by Brenda Bartman on Jun 22nd, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) saw strong trading volume on Monday . Approximately 7,007 shares were traded during mid-day trading, an increase of 41% from the previous session’s volume of 4,973 shares.The stock last traded at $17.26 and had previously closed at $17.12.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective on the stock. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target on the stock. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat, Ascentage Pharma Group International has an average rating of “Buy” and an average price target of $46.43.

Check Out Our Latest Stock Analysis on Ascentage Pharma Group International

Ascentage Pharma Group International Stock Up 0.6%

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The company’s fifty day simple moving average is $21.10 and its two-hundred day simple moving average is $24.16.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million for the quarter. On average, research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -0.96 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently bought and sold shares of AAPG. UBS Group AG increased its position in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter valued at $391,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the third quarter valued at $383,000. Finally, XY Capital Ltd boosted its stake in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.